<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bridgebio Pharma Inc — News on 6ix</title>
<link>https://6ix.com/company/bridgebio-pharma-inc</link>
<description>Latest news and press releases for Bridgebio Pharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bridgebio-pharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354b3678dffbe2df0e5003.webp</url>
<title>Bridgebio Pharma Inc</title>
<link>https://6ix.com/company/bridgebio-pharma-inc</link>
</image>
<item>
<title>BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-launches-health-education-effort-on-often-overlooked-heart-condition-featuring-attrubyr-advocates-morgan-freeman-and-sports-business-icon-howard-h-white</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-launches-health-education-effort-on-often-overlooked-heart-condition-featuring-attrubyr-advocates-morgan-freeman-and-sports-business-icon-howard-h-white</guid>
<pubDate>Tue, 28 Apr 2026 04:00:00 GMT</pubDate>
<description>- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve</description>
</item>
<item>
<title>BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bbot-announces-the-appointment-of-pedro-j-beltran-phd-as-chief-executive-officer-idan-elmelech-as-chief-operating-officer-and-neil-kumar-phd-as-executive-chairman-4</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bbot-announces-the-appointment-of-pedro-j-beltran-phd-as-chief-executive-officer-idan-elmelech-as-chief-operating-officer-and-neil-kumar-phd-as-executive-chairman-4</guid>
<pubDate>Wed, 22 Apr 2026 13:00:00 GMT</pubDate>
<description>Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company’s top executive Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and busi</description>
</item>
<item>
<title>BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-submits-nda-to-fda-for-bbp-418-for-individuals-living-with-lgmd2ir9</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-submits-nda-to-fda-for-bbp-418-for-individuals-living-with-lgmd2ir9</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with</description>
</item>
<item>
<title>Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/acoramidis-significantly-reduces-the-risk-of-all-cause-and-cardiovascular-mortality-in-patients-with-attr-cm-through-month-54</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/acoramidis-significantly-reduces-the-risk-of-all-cause-and-cardiovascular-mortality-in-patients-with-attr-cm-through-month-54</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM</description>
</item>
<item>
<title>BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-to-present-long-term-efficacy-and-safety-data-from-the-attribute-cm-ole-trial-at-the-acc-annual-scientific-sessions</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-to-present-long-term-efficacy-and-safety-data-from-the-attribute-cm-ole-trial-at-the-acc-annual-scientific-sessions</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company</description>
</item>
<item>
<title>BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bbp-418-demonstrates-consistent-efficacy-and-favorable-safety-profile-in-phase-3-fortify-interim-analysis-in-lgmd2ir9</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bbp-418-demonstrates-consistent-efficacy-and-favorable-safety-profile-in-phase-3-fortify-interim-analysis-in-lgmd2ir9</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across</description>
</item>
<item>
<title>BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-to-present-additional-data-from-the-phase-3-fortify-trial-at-the-2026-mda-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-to-present-additional-data-from-the-phase-3-fortify-trial-at-the-2026-mda-clinical-and-scientific-conference</guid>
<pubDate>Wed, 04 Mar 2026 12:30:00 GMT</pubDate>
<description>PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking p</description>
</item>
<item>
<title>BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-commercial-updates</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-commercial-updates</guid>
<pubDate>Tue, 24 Feb 2026 21:01:00 GMT</pubDate>
<description>$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the</description>
</item>
<item>
<title>BridgeBio to Participate in March Investor Conferences</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-to-participate-in-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-to-participate-in-march-investor-conferences</guid>
<pubDate>Mon, 23 Feb 2026 12:30:00 GMT</pubDate>
<description>PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm ESTLeerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat</description>
</item>
<item>
<title>BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-report-fourth-quarter-full-123000860</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-report-fourth-quarter-full-123000860</guid>
<pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
<description>PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To ac</description>
</item>
<item>
<title>BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-reports-positive-phase-3-123000414</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-reports-positive-phase-3-123000414</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory analysis of the key secondary endpoint, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, demonstrating an LS mean trea</description>
</item>
<item>
<title>CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/correcting-replacing-bridgebio-pharma-reports-221000859</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/correcting-replacing-bridgebio-pharma-reports-221000859</guid>
<pubDate>Tue, 27 Jan 2026 22:10:00 GMT</pubDate>
<description>PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows: BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s board of director</description>
</item>
<item>
<title>BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-pharma-reports-inducement-grants-210100617</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-pharma-reports-inducement-grants-210100617</guid>
<pubDate>Tue, 27 Jan 2026 21:01:00 GMT</pubDate>
<description>PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock un</description>
</item>
<item>
<title>BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-prices-offering-550-million-convertible-senior-notes-due-2033-prefund</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-prices-offering-550-million-convertible-senior-notes-due-2033-prefund</guid>
<pubDate>Fri, 16 Jan 2026 05:00:00 GMT</pubDate>
<description>The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturityOffering priced at 0.75% interest</description>
</item>
<item>
<title>BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-continues-long-term-debt-210100129</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-continues-long-term-debt-210100129</guid>
<pubDate>Wed, 14 Jan 2026 21:01:00 GMT</pubDate>
<description>-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity PALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, announced today that it intends to offer, subject to market conditions and other factors, $550 million aggregate principal amount of convertible senior notes</description>
</item>
<item>
<title>BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-announces-commercial-progress-program-153000411</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-announces-commercial-progress-program-153000411</guid>
<pubDate>Mon, 12 Jan 2026 15:30:00 GMT</pubDate>
<description>- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by differentiated clinical data and growing real-world confidence - New TTR amyloid depleter antibody program announced to explore the potential of ATTR-CM disease reve</description>
</item>
<item>
<title>BridgeBio to Participate in the J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-participate-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-participate-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical</description>
</item>
<item>
<title>BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-host-achondroplasia-investor-webinar-friday-january-9th-8-00-am-et-2026-01</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-host-achondroplasia-investor-webinar-friday-january-9th-8-00-am-et-2026-01</guid>
<pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical</description>
</item>
<item>
<title>BridgeBio to Participate in December Investor Conferences</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-participate-december-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/bridgebio-participate-december-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical</description>
</item>
<item>
<title>Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations</title>
<link>https://6ix.com/company/bridgebio-pharma-inc/news/acoramidis-significantly-reduces-all-cause-mortality-overall-attr-cm-variant-and</link>
<guid isPermaLink="true">https://6ix.com/company/bridgebio-pharma-inc/news/acoramidis-significantly-reduces-all-cause-mortality-overall-attr-cm-variant-and</guid>
<pubDate>Sat, 08 Nov 2025 05:00:00 GMT</pubDate>
<description>- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant</description>
</item>
</channel>
</rss>